Advertisement
GlaxoSmithKline
Subscribe to GlaxoSmithKline

The Lead

Isis Pharmaceuticals Earns $18M From GSK for Advancing ISIS-TTR Rx

October 9, 2014 8:14 am | News | Comments

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.  Including this $18M milestone payment, Isis has generated $45M of the $70M in upfront and milestone payments Isis is eligible to earn for advancing ISIS-TTRRx in development.

Novartis Says Three Members of Executive Committee to Leave Company

October 8, 2014 9:09 am | News | Comments

Novartis confirmed today that following completion of the transactions with GlaxoSmithKline and...

Drug Firms Redirect Sales Pitch to Hospitals

October 3, 2014 8:40 am | Videos | Comments

Pharmaceutical companies are refining their sales strategy. GlaxoSmithKline's Dierdre Connelly...

Experimental Ebola Vaccine Processed in Maryland

October 2, 2014 10:48 am | News | Comments

The National Institute of Allergy and Infectious Diseases says an experimental Ebola vaccine is...

View Sample

FREE Email Newsletter

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing

October 1, 2014 8:35 am | News | Comments

The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumor types.        

Analyst: GSK's $490M Fine to Spark Pharma Strategy Shift in Emerging Markets

September 24, 2014 11:21 am | News | Comments

The scandal and its repercussions will be felt deep into Big Pharma’s operations in emerging markets, causing a fundamental shift in product marketing approaches involving physicians.           

Avalon Ventures and GlaxoSmithKline Launch Two New Companies

September 22, 2014 8:08 am | News | Comments

Silarus Therapeutics and Thyritope Biosciences each will receive up to $10M in Series A financing and R&D support from Avalon Ventures and GSK. Both companies will be located at COI Pharmaceuticals in San Diego, the community of innovation established by Avalon Ventures to provide operational support, a fully equipped R&D facility and an experienced leadership team to its life science portfolio companies.

Advertisement

China Fines GSK $492M for Bribery

September 19, 2014 5:47 am | by Joe Mcdonald - AP Business Writer - Associated Press | News | Comments

A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been sentenced to prison in a bribery case but may never have to serve that time. China's official Xinhua News Agency said Briton Mark Reilly and his Chinese co-defendants were given a three-year reprieve at their sentencing Friday.

First UK Volunteer Gets Experimental Ebola Vaccine

September 17, 2014 12:51 pm | by The Associated Press | News | Comments

British scientists say a former nurse has become the first person in the country to receive an experimental Ebola vaccine in an early trial to test its safety. Ruth Atkins, 48, got the injection on Wednesday in Oxford, the first of 60 healthy volunteers in the U.K. who will receive the vaccine.

Monkey Study: Ebola Vaccine Works, Needs Booster

September 8, 2014 8:13 am | by LAURAN NEERGAARD, AP Medical Writer | News | Comments

New monkey studies show that one shot of an experimental Ebola vaccine can trigger fast protection, but the effect waned unless the animals got a booster shot made a different way.            

US to Begin Safety Testing Ebola Vaccine Next Week

August 28, 2014 9:26 am | by SETH BORENSTEIN, AP Science Writer | News | Comments

The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. It will test 20 healthy adult volunteers to see if the virus is safe and triggers an adequate response in their immune systems.

Ligand Partner GlaxoSmithKline Receives FDA Approval for Promacta®/Revolade™

August 27, 2014 8:07 am | News | Comments

Ligand Pharmaceuticals Incorporated announced that its partner GlaxoSmithKline has received approval of a supplemental New Drug Application (sNDA) for the once-daily use of Promacta®/Revolade™ (eltrombopag) in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).

Advertisement

Health Canada OKs GSK's Plan to Fix Quebec Flu Vaccine Plant Problems

August 12, 2014 8:15 am | by Helen Branswell, The Canadian Press | News | Comments

Health Canada says it has approved a plan by GlaxoSmithKline to fix contamination problems it has been experiencing at its Ste. Foy, Que., flu vaccine production plant. The department says GSK's action plan and the timelines proposed in it are satisfactory.

China Jails British-US Investigator Couple

August 8, 2014 1:29 pm | News | Comments

A Briton and an American were sentenced to prison on Friday on charges of illegally trading in the personal details of Chinese citizens after they testified they bought such information to help companies combat fraud.          

British-US Investigative Couple on Trial in China

August 8, 2014 12:30 am | by The Associated Press | News | Comments

A British man on trial with his American wife for illegally obtaining and selling private information about Chinese nationals says he buys such information from other consulting companies. Peter William Humphrey made the comments Friday after his trial opened in Shanghai.

China to Put Glaxo Investigators On Trial

July 29, 2014 5:30 am | by The Associated Press | News | Comments

A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens. The Shanghai No. 1 Intermediate People's Court said Tuesday that Yingzeng Yu and her husband Peter Humphrey will have a "public trial."

GSK Asks European Regulator to OK Malaria Shot

July 24, 2014 8:18 am | News | Comments

The experimental shot is the most advanced candidate vaccine for malaria but results from previous trials have been disappointing. Research published in 2012 showed the shot only reduced malaria cases by about 30 percent in babies aged six to 12 weeks, the target age for immunization.

Advertisement

GSK's CEO and CFO Discuss the Company's Second Quarter Results

July 23, 2014 9:13 am | Videos | Comments

GSK CEO Sir Andrew Witty and CFO Simon Dingemans on the group’s Q2 2014 results and strategy update.                         

Report: GSK Flu Vaccine Plant Inspection Finds Ten Actionable Issues

July 23, 2014 8:14 am | by Helen Branswell, The Canadian Press | News | Comments

A recent Health Canada inspection of the country's only flu vaccine production plant identified 10 issues that need to be addressed, a report from the regulatory agency reveals. The summary report of the June inspection said none of the problems found poses a critical risk to public health, but seven fall into the major observation category.

GSK and Theravance Initiate Phase III Program for COPD Treatment

July 16, 2014 8:53 am | News | Comments

GlaxoSmithKline and Theravance today announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease (COPD).

China Indicts US, British Nationals Involved In GSK Investigation

July 13, 2014 11:26 pm | by The Associated Press | News | Comments

Chinese authorities formally indicted two corporate investigators, an American and Briton, for allegedly illegally obtaining and selling private information, state media reported Monday. Prosecutors in Shanghai filed charges against British investigator Peter Humphrey and his wife Yingzeng Yu, a U.S. citizen, at the city's No. 1 Intermediate People's Court, the official Xinhua News Agency said.

US Officials Barred from American's Trial in China

July 4, 2014 5:25 am | by The Associated Press | News | Comments

A U.S. Embassy spokesman says diplomats are barred from the trial in Shanghai of an American investigator for GlaxoSmithKline and her British husband who are charged with improperly selling personal information. Spokesman Nolan Barkhouse said Friday that the U.S. government is concerned about lack of access to the trial of Yu Yingzeng and husband Peter Humphrey in August.

GlaxoSmithKline Agrees to $105M Settlement

June 4, 2014 6:32 pm | by The Associated Press | News | Comments

GlaxoSmithKline PLC will pay $105 million to dozens of states to settle allegations that it marketed drugs for uses unapproved by federal regulators. Lawsuits filed in 44 states and the District of Columbia alleged that the British drugmaker misrepresented the uses and qualities of its asthma drug Advair and the antidepressants Paxil and Wellbutrin.

UK Serious Fraud Office Investigates GSK

May 27, 2014 5:32 pm | by The Associated Press | News | Comments

Britain's Serious Fraud Office says it has opened a criminal investigation into the commercial practices of GlaxoSmithKline PLC and its subsidiaries. The company has faced a series of investigations into its activities in recent months including a major corruption probe in China.

PERNIX to Acquire TREXIMET® Tablets for Migraine From GSK

May 15, 2014 8:39 am | News | Comments

Pernix Therapeutics Holdings has signed an agreement with GlaxoSmithKline to acquire the U.S rights to Treximet® (sumatriptan/naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults.     

British Executive Accused in China Drug Bribery

May 14, 2014 7:57 am | by DIDI TANG, Associated Press | News | Comments

Chinese police have accused a British executive of GlaxoSmithKline of leading a sprawling scheme to bribe doctors and hospitals to use its drugs. The announcement was the first time a foreign employee in China of British-based GSK was accused in the investigation announced last July.

Ligand Partner GSK Gains Priority Review Designation for Promacta™/Revolade™ for Severe Aplastic Anemia

April 30, 2014 8:01 am | News | Comments

Ligand Pharmaceuticals has announced that the FDA has granted its partner GlaxoSmithKline Priority Review designation for Promacta™/Revolade™ (eltrombopag) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.

Deal Flurry Shows Drug Makers’ Move to Specialization

April 24, 2014 8:58 am | Videos | Comments

The recent flurry of drug deals shows how the global pharmaceutical industry is reversing course, as companies narrow their focus after decades of diversifying their drug portfolios.            

Investor Pressure Pushing Pharmaceutical M&A Deals

April 22, 2014 7:31 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading